Description:
Cervical cancer screening is measured by the percentage of women, 21 to 64 years of age who were screened for cervical cancer using either of the following criteria:
- Women 21 to 64 years of age who had cervical cytology performed within the last 3 years.
- Women 30 to 64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Women 30 to 64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.
Note: Evidence of hrHPV testing within the past five years also captures patients who had co-testing; therefore, additional methods to identify co-testing are not necessary.
Documentation:
- For women age 24-64 as of Dec. 31 of the measurement year who had cervical cytology
during the measurement year or the two years prior to the measurement year, documentation
in the medical record must include both of the following:
o A note indicating the date when the cervical cytology was performed
o The result or finding
2. For women age 30-64 as of Dec. 31 of the measurement year who: 1) had cervical hrHPV
testing during the measurement year or the four years prior to the measurement years, and 2)
were 30 years or older as of the date of testing, documentation must include both:
o A note indicating the date the hrHPV test was performed; generic documentation stating
HPV test counts as evidence of hrHPV test
o The results or findings
Documentation that will not be accepted for this measure:
- Biopsies do not count
- Lab results that state the sample was inadequate or that no cervical cells were present are
not acceptable unless it is also stated this finding is consistent with a hysterectomy - Documenting hysterectomy is not sufficient; should note if the hysterectomy resulted in the
loss of the cervix and include terms like total, complete or radical hysterectomy
Exclusions:
1.Women who have had a total, complete or radical vaginal or abdominal hysterectomy with no
residual cervix, cervical agenesis or acquired absence of cervix; prior to Dec. 31 of the
measurement year
2. Hospice or palliative care during measurement years
3. Documentation of vaginal hysterectomy meets criteria for documentation of hysterectomy with
no residual cervix
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
All summaries of the measures contained herein are reproduced w ith permission from HEDIS MY2020 and MY2021, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
Find this type op information useful? Follow my blog/website for more medical billing, coding guideline updates, reimbursement/medical coverage updates, HEDIS updates and more.
Recent Blog Posts:
- HEDIS Measure: Immunizations for Adolescent
- UHC Minnesota Community Plan: non-emergency transport
- EmblemHealth Commercial Plans: site of care change – adding 170 new injectable and infusion meds to the list
- Aetna: Reimbursement for evaluations with G2082 and G2083 codes…
- Cigna to add more codes to their Virtual Vare Reimbursement Policy and make them permanent, however…
KR2 Medical Billing 